AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Telegram Restored on Apple App Store After Temporary Removal 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 09, 2018 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT) will announce its financial results for the fourth quarter and fiscal year ended 31 January 2018 on 11 April 2018.
Summit will host a conference call and webcast the same day to discuss its operational progress at 1:00pm BST / 8:00am EDT. Conference call and webcast information will be included in the full year results press release. A replay of the call will also be available through the Company's website, www.summitplc.com, shortly after its conclusion.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: | 44 (0)1235 443 951 |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP (Nominated Adviser) | Tel: | +44 (0)20 7213 0880 |
| Liam Murray / Tony Rawlinson | ||
| N+1 Singer (Joint Broker) | Tel: | +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer | ||
| Panmure Gordon (Joint Broker) | Tel: | +44 (0)20 7886 2500 |
| Freddy Crossley, Corporate Finance | ||
| Tom Salvesen, Corporate Broking | ||
| MacDougall Biomedical Communications (US) | Tel: | +1 781 235 3060 |
| Karen Sharma | [email protected] | |
| Consilium Strategic Communications (UK) | Tel: | +44 (0)20 3709 5700 |
| Mary-Jane Elliott / Jessica Hodgson / | [email protected] | |
| Philippa Gardner / Rosie Phillips |
-END-
